BRISTOL MYERS SQUIBB : U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Press/Media: Press / Media

PeriodFeb 5 2016

Media coverage

1

Media coverage

  • TitleBRISTOL MYERS SQUIBB : U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outlet4 Traders
    CountryUnited States
    Date2/5/16
    PersonsFred Poordad
View all 1
View less